Weekly intelligence, FDA-aligned frameworks, and actionable AI guides — built exclusively for pharmaceutical professionals who refuse to fall behind.
No credit card for the first 7 days • Cancel anytime
1
FDA AI Guidance Issued
January 2025 draft framework
75%
Pharma Companies Exploring AI
Across drug development lifecycle
$2.6B
Average Drug Development Cost
AI can compress timelines and reduce waste
0
FDA-Aligned AI Governance Guides
Before Briefing Layer: Scientist
The Problem
FDA expects a risk-based credibility assessment for AI models in your submission, but there is no clear playbook for what that documentation looks like or how rigorous it needs to be.
Every edition translates FDA guidance into actionable validation frameworks with documentation templates, credibility assessment checklists, and submission-ready examples.
Your AI models are trained on data of uncertain quality and provenance. FDA's guidance makes data quality a foundational requirement, but your data governance is inconsistent across programs.
Data quality assessment frameworks mapped to FDA's three governance domains, with practical tools for auditing training data, documenting lineage, and identifying bias before it reaches a submission.
Competitors are using AI to compress discovery timelines by months. You are evaluating the same tools but cannot determine which meet GxP validation requirements for regulated use.
Compliance-vetted tool reviews that evaluate scientific rigor, GxP readiness, and FDA alignment for every major pharma AI platform — so you can adopt with confidence and speed.
Your pharmacovigilance team is overwhelmed with case volume and FDA expects AI-assisted signal detection, but no one has defined the validation requirements or human oversight model.
Ready-to-adapt AI pharmacovigilance governance frameworks, signal detection validation protocols, and human oversight models built specifically for regulated safety operations.
The Platform
Eight integrated products that make AI adoption safe, strategic, and practical.
Curated intelligence on AI developments that affect drug development, filtered for relevance and scored for regulatory impact. Read in 8 minutes.
Listen to each edition between meetings or during your commute. AI-generated audio with pharma-specific context and emphasis on actionable takeaways.
Benchmark your organization's AI governance, technology adoption, and training against industry peers. 17 questions mapped to FDA guidance, GxP requirements, and data quality standards.
Deep-dive reviews of Insilico Medicine, Recursion, Medidata AI, Veeva Vault AI, and more. Each review covers GxP readiness, data handling, FDA alignment, and scientific validation.
Ask questions about FDA AI guidance, validation requirements, or implementation strategy. Grounded in FDA draft guidance, EMA positions, ICH guidelines, and GxP expectations.
Instant notifications when FDA issues AI guidance, EMA updates its reflection paper, or ICH publishes new AI/ML guidelines affecting drug development.
Plus: quarterly deep-dive reports, monthly live tool demos, and breaking regulatory alerts.
What Subscribers Say
“We needed one source that could translate FDA's AI guidance into actionable validation frameworks our teams could actually implement. Briefing Layer: Scientist is that source.”
Dr. Katherine Huang
SVP R&D, Top 20 Pharma
“Our clinical operations team went from ad hoc AI use to a governed, FDA-aligned framework in eight weeks. The credibility assessment templates alone were worth the subscription.”
James Okonkwo
VP Clinical Operations, Biotech
“As a CRO, our clients expect us to have AI governance sorted. Briefing Layer: Scientist gave us the frameworks to lead that conversation instead of reacting to it.”
Dr. Priya Sharma
Chief Data Officer, Global CRO
Pricing
No tiers, no upsells, no paywalled features within the platform.
14-day free trial • Cancel anytime
No credit card required for the first 7 days
Refer a colleague and earn a free month ($750 credit). Max 3 per year.
No. Briefing Layer: Scientist provides educational intelligence about AI in pharmaceutical development. It does not constitute regulatory advice. Always consult qualified regulatory counsel or experienced regulatory affairs professionals for guidance on specific submission strategies, validation requirements, or FDA interactions.
Our content serves pharmaceutical professionals at every organizational scale — from biotech founders to top 20 pharma R&D leaders. Biotechs often face the same FDA validation requirements with fewer resources to interpret guidance. The scorecard and tool reviews are designed to scale from pre-IND startups to global pharmaceutical companies.
Each tool review assesses GxP validation readiness, evaluates data handling and security practices against regulatory expectations, tests scientific rigor of model outputs, and maps alignment to FDA's risk-based credibility assessment framework. We also review vendor qualification documentation and change management processes.
Our content is designed for the intersection of science, regulation, and implementation. Regulatory affairs professionals benefit from translated FDA guidance and submission-ready frameworks. R&D leaders get tool evaluations and governance templates. Data scientists get validation protocols. The scorecard benchmarks the entire organization's AI maturity.
We monitor FDA, EMA, ICH, and NIH publications daily. Regulatory alerts are sent within 24 hours of significant guidance releases, enforcement actions, or policy signals. The weekly briefing synthesizes the most important developments with drug-development-specific analysis and action items.
Your competitors are already experimenting. The question isn't whether to adopt — it's whether you'll lead the transition or chase it.
Start Your Free Trial14 days free • No credit card for the first 7 • Cancel anytime